Sex disparities in aldosterone-dependent renal Na+ transport and blood pressure control

Information

  • Research Project
  • 10298925
  • ApplicationId
    10298925
  • Core Project Number
    R01DK125464
  • Full Project Number
    1R01DK125464-01A1
  • Serial Number
    125464
  • FOA Number
    PA-20-185
  • Sub Project Id
  • Project Start Date
    8/3/2021 - 2 years ago
  • Project End Date
    7/31/2026 - 2 years from now
  • Program Officer Name
    MARIC-BILKAN, CHRISTINE
  • Budget Start Date
    8/3/2021 - 2 years ago
  • Budget End Date
    7/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    8/3/2021 - 2 years ago
Organizations

Sex disparities in aldosterone-dependent renal Na+ transport and blood pressure control

Hypertension remains a major public health challenge worldwide despite the abundance of available therapeutic options. Inappropriate therapy and patient non-compliance are the main factors accounting for poor blood pressure (BP) control. Identification of the mechanisms responsible for elevation of BP in specific patient cohorts is critical to effectively combat hypertension and related diseases. Excessive sodium retention via the Epithelial Na? Channel (ENaC) hampers the ability of the kidney to make precise adjustments to sodium balance and is a common pathogenic determinant of hypertension. Cumulative evidence suggests that biological sex is a pivotal covariate affecting the development and pathophysiology of hypertension in the human population and animal models. Our proposal introduces a novel concept that regulation of Na? reabsorption in the kidney and renal BP control rely on sex-specific mechanisms governing ENaC activity in the aldosterone-sensitive distal nephron. We and others have previously shown that aldosterone antagonism with mineralocorticoid receptor (MR) inhibitors is insufficient to reduce excessive renal ENaC activity and fails to effectively attenuate BP in male rodents with angiotensin II (Angil) dependent hypertension. Our pilot experiments reveal that hypertensive female rats with salt-sensitive and Angil-dependent hypertension benefit from MR antagonism and exhibit a stronger BP reduction, when compared to males. MR blockade is also much more potent at decreasing renal ENaC activity in Ang II-infused female rats than in males. Our findings strongly suggest that sensitivity of renal ENaC to aldosterone is an unrecognized sex-specific mechanism of chronic BP regulation. The proposal is built around the central hypothesis that hypersensitivity of ENaC to aldosterone accounts for a prevalent contribution of aldosterone to renal BP control in hypertensive female rats, when compared to males. We propose to test the hypothesis with two complementary specific aims addressing a clinically relevant problem of adequate blood pressure control at the molecular, cellular {Aim 1) and integrative {Aim 2) levels. Aim 1 will test the hypothesis that sensitivity of renal ENaC to aldosterone is greater in hypertensive female rats than in males. Our hypothesis predicts that female sex steroids positively modulate MR-dependent signaling in the kidney to augment the response of ENaC to aldosterone in hypertensive females. Aim 2 will test the hypothesis that aldosterone dominates renal BP control in hypertensive female, but not in male, rats. Our hypothesis predicts that aldosterone-MR axis is the primary driver of hypertension and renal damage in females and MR antagonism will be dramatically more effective at reducing BP and renal injury in hypertensive females than in males. Successful completion of this proposal will differentiate the pathophysiological mechanisms governing Na? retention in hypertensive males and females and provide the missing pre-clinical evidence to optimize the use of MR antagonists in hypertensive patients of both sexes.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R01
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
    327685
  • Indirect Cost Amount
    128480
  • Total Cost
    456165
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIDDK:456165\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    IVPP
  • Study Section Name
    Integrative Vascular Physiology and Pathology Study Section
  • Organization Name
    AUGUSTA UNIVERSITY
  • Organization Department
    PHYSIOLOGY
  • Organization DUNS
    809593387; 966668691
  • Organization City
    AUGUSTA
  • Organization State
    GA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    309120004
  • Organization District
    UNITED STATES